Modified tissue cardiomyoplasty and tissue engineered heart valves for congenital heart disease surgery

用于先天性心脏病手术的改良组织心肌成形术和组织工程心脏瓣膜

• 批准号: 129619891
• 负责人: Professor Dr. Axel Haverich
• 金额: --
• 依托单位: Klinik für Herz-, Thorax-, Transplantations- und Gefäßchirurgie (HTTG)
• 依托单位国家: 德国
• 项目类别: Research Grants
• 财政年份: 2009
• 资助国家: 德国
• 起止时间: 2008-12-31 至 2013-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/129619891?language=en
• 关键词: Modified; tissue; cardiomyoplasty; engineered; heart

Materials for right ventricular outflow tract (RVOT) reconstruction are still a matter of major concern in surgery for congenital heart disease (CHD). Postoperative right ventricular (RV) failure is a crucial cause of late morbidity and mortality. Recently, many research projects have focused on regenerative medicine. Tissue engineered (TE) heart valves and TE myocardial patches seem to be very promising therapeutical strategies for clinical use. Based on this background, we are establishing a research consortium between Hannover and Osaka with the aim to develop an integrated surgical strategy for the reconstruction of the RVOT. The presented research project consists of four parts:Assessment of clinical features of RVOT pathologies and RV failure after surgical repair of complex CHD by the establishment and analysis of a clinical database. Construction of TE myocardial patches based on biological vascularized matrices (BioVaM) and myocardial cell sheets for RVOT reconstruction. Development of a combined RVOT graft consisting of a TE heart valve and an autologous myocardial patch consisting of a segment of small intestine (autologous vascularized matrix = AutoVaM). Development of a combined RVOT graft consisting of a TE heart valve and a TE myocardial patch (BioVaM combined with myocardial cell sheets). Endpoint of this project is the development of a clinically applicable TE graft for RVOT reconstruction that is suitable for various kinds of RVOT pathologies.

右室流出道（RVOT）重建材料是先天性心脏病（CHD）外科治疗中的一个重要问题。术后右心室（RV）衰竭是晚期发病率和死亡率的重要原因。最近，许多研究项目都集中在再生医学上。组织工程心脏瓣膜和组织工程心肌补片是一种非常有前景的临床治疗策略。基于这一背景，我们正在汉诺威和大坂之间建立一个研究联盟，旨在制定RVOT重建的综合手术策略。本研究项目包括四个部分：通过建立和分析临床数据库，评估复杂CHD手术修复后RVOT病理和RV衰竭的临床特征。基于生物血管化基质（BioVaM）和心肌细胞片构建TE心肌补片用于RVOT重建。由TE心脏瓣膜和由一段小肠组成的自体心肌补片（自体血管化基质= AutoVaM）组成的组合RVOT移植物的开发。开发由TE心脏瓣膜和TE心肌补片组成的组合RVOT移植物（BioVaM与心肌细胞片组合）。本项目的终点是开发适用于各种RVOT病理的RVOT重建的临床适用TE移植物。